Literature DB >> 20053923

Influence of cell background on pharmacological rescue of mutant CFTR.

Nicoletta Pedemonte1, Valeria Tomati, Elvira Sondo, Luis J V Galietta.   

Abstract

Cystic fibrosis (CF) is caused by mutations in the CFTR chloride channel. Deletion of phenylalanine 508 (F508del), the most frequent CF mutation, impairs the maturation and gating of the CFTR protein. Such defects may be corrected in vitro by pharmacological modulators named as correctors and potentiators, respectively. We have evaluated a panel of correctors and potentiators derived from various sources to assess potency, efficacy, and mechanism of action. For this purpose, we have used functional and biochemical assays on two different cell expression systems, Fischer rat thyroid (FRT) and A549 cells. The order of potency and efficacy of potentiators was similar in the two cell types considered, with phenylglycine PG-01 and isoxazole UCCF-152 being the most potent and least potent, respectively. Most potentiators were also effective on two mutations, G551D and G1349D, that cause a purely gating defect. In contrast, corrector effect was strongly affected by cell background, with the extreme case of many compounds working in one cell type only. Our findings are in favor of a direct action of potentiators on CFTR, possibly at a common binding site. In contrast, most correctors seem to work indirectly with various mechanisms of action. Combinations of correctors acting at different levels may lead to additive F508del-CFTR rescue.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053923     DOI: 10.1152/ajpcell.00404.2009

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  66 in total

1.  Endogenous surface expression of ΔF508-CFTR mediates cAMP-stimulated Cl(-) current in CFTR(ΔF508/ΔF508) pig thyroid epithelial cells.

Authors:  Yonghai Li; Suhasini Ganta; Peying Fong
Journal:  Exp Physiol       Date:  2011-09-23       Impact factor: 2.969

2.  CFTR regulation in human airway epithelial cells requires integrity of the actin cytoskeleton and compartmentalized cAMP and PKA activity.

Authors:  Stefania Monterisi; Maria Favia; Lorenzo Guerra; Rosa A Cardone; Domenico Marzulli; Stephan J Reshkin; Valeria Casavola; Manuela Zaccolo
Journal:  J Cell Sci       Date:  2012-02-02       Impact factor: 5.285

3.  Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.

Authors:  Jia Liu; Hermann Bihler; Carlos M Farinha; Nikhil T Awatade; Ana M Romão; Dayna Mercadante; Yi Cheng; Isaac Musisi; Walailak Jantarajit; Yiting Wang; Zhiwei Cai; Margarida D Amaral; Martin Mense; David N Sheppard
Journal:  Br J Pharmacol       Date:  2018-02-22       Impact factor: 8.739

4.  Hollow Micropillar Array Method for High-Capacity Drug Screening on Filter-Grown Epithelial Cells.

Authors:  Byung-Ju Jin; Sujin Lee; Alan S Verkman
Journal:  Anal Chem       Date:  2018-05-30       Impact factor: 6.986

5.  Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.

Authors:  Puay-Wah Phuan; Baoxue Yang; John M Knapp; Alex B Wood; Gergely L Lukacs; Mark J Kurth; A S Verkman
Journal:  Mol Pharmacol       Date:  2011-07-05       Impact factor: 4.436

6.  Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.

Authors:  Peter M Haggie; Puay-Wah Phuan; Joseph-Anthony Tan; Haijin Xu; Radu G Avramescu; Doranda Perdomo; Lorna Zlock; Dennis W Nielson; Walter E Finkbeiner; Gergely L Lukacs; Alan S Verkman
Journal:  J Biol Chem       Date:  2016-11-28       Impact factor: 5.157

7.  Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect.

Authors:  Julien Colas; Grazyna Faure; Emilie Saussereau; Stéphanie Trudel; Wael M Rabeh; Sara Bitam; Ida Chiara Guerrera; Janine Fritsch; Isabelle Sermet-Gaudelus; Noëlie Davezac; Franck Brouillard; Gergely L Lukacs; Harald Herrmann; Mario Ollero; Aleksander Edelman
Journal:  Hum Mol Genet       Date:  2011-10-28       Impact factor: 6.150

8.  Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform.

Authors:  John P Holleran; Matthew L Glover; Kathryn W Peters; Carol A Bertrand; Simon C Watkins; Jonathan W Jarvik; Raymond A Frizzell
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

9.  Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.

Authors:  Puay-Wah Phuan; Jung-Ho Son; Joseph-Anthony Tan; Clarabella Li; Ilaria Musante; Lorna Zlock; Dennis W Nielson; Walter E Finkbeiner; Mark J Kurth; Luis J Galietta; Peter M Haggie; Alan S Verkman
Journal:  J Cyst Fibros       Date:  2018-06-12       Impact factor: 5.482

Review 10.  Local modulation of cystic fibrosis conductance regulator: cytoskeleton and compartmentalized cAMP signalling.

Authors:  Stefania Monterisi; Valeria Casavola; Manuela Zaccolo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.